 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Sana Biotechnology
SANA
conference date: November 2, 2022, press release only
Sana Biotechnology a Buy for Potential Cancer Therapies [June 27, 2022 at Seeking Alpha]
| 2019 | |||
| Sana Biotechnology Q2 2022 |
Sana Biotechnology Q3 2022 |
||
| Aug. 4, 2022 | Nov. 2, 2022 | ||
Sana Biotechnology (SANA) is a preclinical-stage biotechnology company specializing in cell therapies for blood cancers.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BMY |
| CLDX |
| CDTX |
| DRNA |
| EPZM |
| GILD |
| GLYC |
| ILMN |
| IMGN |
| INCY |
| INKT |
| INO |
| IONS |
| MCHP |
| MRNA |
| PLX |
| RETA |
| REGN |
| RNA |
| SAGE |
| SGEN |
| SYRS |
| VBLT |
| VSTM |
| VRTX |
| WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2022 William P. Meyers